SCHEMBL7183576

SCHEMBL7183576

COc1cc(OC)c(C(=O)C(P=O)c2ccccc2)c(OC)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.44
CYP3A4 P08684 2/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
ATM Q13315 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MEN1 O00255 4/20 0.43
USP2 O75604 1/20 0.42
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ABCG2 Q9UNQ0 1/20 0.41
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HTT P42858 1/20 0.40
PTPN1 P18031 1/20 0.40
TACR1 P25103 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7185486 0.87 CA12 (0.51) KMT2AMAPTMEN1SMN1; SMN2TDP1
SCHEMBL29504856 0.81 LMNA (0.47) KMT2ACYP3A4TP53MAPTATM
SCHEMBL7180696 0.80 TDP1 (0.46) KMT2ACYP3A4TP53MAPTATM
SCHEMBL7177669 0.79 TDP1 (0.43) KMT2ACYP3A4TP53MAPTATM
SCHEMBL7183680 0.79 KMT2A (0.41) KMT2ACYP3A4TP53MAPTATM
SCHEMBL7185609 0.78 FABP4 (0.46) KMT2AMAPTMEN1SMN1; SMN2TDP1
SCHEMBL7174607 0.78 TDP1 (0.44) KMT2ACYP3A4TP53MAPTATM
SCHEMBL27554103 0.76 KMT2A (0.46) KMT2ACYP3A4TP53MAPTATM
SCHEMBL7190445 0.76 TDP1 (0.42) KMT2ACYP3A4TP53MAPTATM
SCHEMBL23094065 0.75 KMT2A (0.42) KMT2ACYP3A4TP53MAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885CYP3A4 1652/4885TP53 3575/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885CYP3A4 1881/4885TP53 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.